Earnings ·
Apyx Medical reports Q2 revenue of $13.9 million, up 22%, as net loss narrows to $0.07 per share
APYXApyx Medical Corp
Apyx Medical Corporation reported second quarter 2026 financial results for the period ended June 30, 2026. Total revenue increased 22% to $13.9 million from $11.4 million in the prior year, driven by a 28% growth in the Surgical Aesthetics segment to $12.4 million. The company initiated limited commercial shipments of its reusable power liposuction handpiece for the AYON platform in June 2026 following expanded FDA clearance. Net loss attributable to stockholders narrowed to $3.2 million, or $0.07 per share, compared to a $3.8 million loss in the previous year. Adjusted EBITDA improved significantly, with a loss of $0.7 million versus $2.0 million previously. The company reaffirmed its full-year 2026 revenue guidance of $59.0 million to $60.0 million and reported cash and cash equivalents of $27.6 million as of June 30, 2026. Apyx Medical Corporation operates in the surgical aesthetics industry, developing and marketing medical devices such as Renuvion and the AYON Body Contouring System.